ENSG00000267968 and prostate carcinoma: KLK3e enhances the expression of AR-regulated genes in prostate tumors, providing the potential for eRNA-targeted therapy and the evaluation of androgen deprivation therapy in prostate cancer patients by measuring eRNA expression [13].